NasdaqGS:MPLTBiotechs
MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus
MapLight Therapeutics (MPLT) has drawn investor attention recently as its clinical-stage central nervous system pipeline, including candidates for schizophrenia, Alzheimer’s disease psychosis and Parkinson’s disease, trades around $36.56 with a market value near $1.66 billion.
See our latest analysis for MapLight Therapeutics.
For context, MapLight Therapeutics’ share price return has been strong over 2024, with a year to date gain of 118.01% and a 90 day share price return of 19.32%...